Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC STOCKHOLM, SWEDEN – May 8, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has randomized its first two patients to the second part of the ongoing clinical phase 1b/2 study of golexanolone in patients with Primary Biliary Cholangitis, PBC. Top-line results are expected in first half of 2025. Umecrine Cognition is developing a new class of drugs to alleviate cognitive symptoms caused by liver disease....
Karolinska Developments portföljbolag Umecrine Cognition inleder andra delen av bolagets fas 1b/2-studie i PBC STOCKHOLM, SVERIGE 8 maj 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition har randomiserat de första två patienterna till den andra delen av bolagets pågående kliniska fas 1a/2-studie med golexanolon i patienter med primär biliär kolangit, PBC. Top line-resultat beräknas presenteras under det första halvåret 2025. Umecrine Cognition utvecklar en helt ny typ av läkemedel för att lindra kognitiva symtom orsakade av leversjukd...
>T1 inférieur aux attentes à cause surtout d’Americas - Comme Acerinox et Aperam avant lui, Outokumpu a déçu le marché avec des résultats T1 inférieurs aux attentes et une guidance T2 assez modeste. Comme chez ses deux concurrents, cette situation reflète pour partie des problèmes opérationnels (grève en Finlande, maintenance plus longue que prévu aux USA) et un environnement de marché peu propice surtout en Europe. L’EBITDA ajusté T1 est ainsi ressorti à seulement 38...
>Q1 2024: organic revenue growth of 6.1% and operating EBIT margin of 12.1% - Knorr-Bremse reported its Q1 2024 results this morning. Order intake was better than expected (at € 2.1bn, or 1.07x of book-to-bill), and both divisions were ahead of expectations with organic growth of 8.2% for orders in rail (RVS), and a decline of 9.2% in trucks (CVS). The group generated revenues of € 1.974bn (consensus at € 1.962bn), up 6.1% in organic terms (css at 5.1%) and an operati...
IDEX Biometrics is bringing biometric cards to market with large smart card manufacturer in South Asia Oslo, Norway, 8 May 2024 – IDEX Biometrics and one of the largest smart card manufacturers in South Asia are deploying smart cards across Asia and globally. With over 3 billion cards manufactured to date and a production capacity of 25 million cards monthly, this partner will support IDEX Biometrics continued expansion and growth across Asia Pacific, Middle East, Africa, and the USA. Accredited by Visa, Mastercard and RuPay and with a growing client portfolio of banks, government agencie...
A director at Thredup Inc sold/sold after exercising options 424,268 shares at 1.910USD and the significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...
>Revenues up 17%, in-line with full year guidance - Directional revenues in 24Q1 are up 17% to $ 871m, with Lease & Operate up 22% to $ 554m and Turnkey up 9% to $ 316m. Fleet uptime was 97.6%,2024 guidance for directional revenue is maintained at c. $ 3.5bn of which c. $ 2.2bn from Lease & Operate and c. $ 1.3bn from Turnkey. Directional EBITDA guidance is maintained at c. $ 1.2bn.Dividend & SBB. The AGM on 12 April approved the proposed $ 150m cash dividen...
>Q3 2023/24 sales of € 94m (+4%, o/w +2% org), close to our forecasts - Claranova reported yesterday evening Q3 2023/24 sales of € 94m, up 4% year-on-year on a reported basis and 2% organically. This figure was close to our forecast (ODDO BHF: € 97m). By division, 1/ PlanetArt (65% of Q3 sales) reported a 2% organic decline. While this division is still not back on the organic growth path, sales have stabilised in the context of the priority given to profitability; 2/...
Moody's Ratings (Moody's) has upgraded the ratings on five classes of notes issued by Avanti AU Auto ABS 2023-1 Trust in respect of the Series 2023-1. IMPORTANT NOTICE: MOODY'S RATINGS AND PUBLICATIONS ARE NOT INTENDED FOR USE BY RETAIL INVESTORS. SUCH USE WOULD BE RECKLESS AND INAPPROPRIATE. SEE ...
Elecster-konsernin osavuosikatsaus 1.1. – 31.3.2024 ELECSTER OYJ OSAVUOSIKATSAUS 8.5.2024 KLO 10:15 ELECSTER -KONSERNIN OSAVUOSIKATSAUS 1.1. – 31.3.2024 Osakekohtainen tulos kääntyi voitolliseksi YHTEENVETO Liikevaihto 8,2 MEUR (1-3/2023: 8,6 MEUR)Liikevoitto 0,6 MEUR (0,7 MEUR)Tulos ennen veroja 0,9 MEUR (-0,1 MEUR)Tulos/osake 0,17 EUR (-0,11 EUR)Omavaraisuusaste 51,0 % (53,0 %) TOIMINTAYMPÄRISTÖEKP:n asiantuntijoiden maaliskuun 2024 kokonaistaloudellisten arvioiden muk...
AB InBev: Busy BEES. Ahold Delhaize: Small beat, comforting confirmation of 2024 guidance. AMG: 1Q24 better than expected, FY guidance intact, strategic projects on schedule. Bekaert: Soft start to the year with 7% sales miss, FY guidance maintained. Euronav: Transformation at full speed. Marel: Another lacklustre quarter. Montea: 2025 guidance raised, valuations moving into positive territory. SBM Offshore: In-line Q1 trading update. Sif Group: Preview - normal quarter e...
Interim Report Q1 2024 2024 off to a good start with continued revenue growth Revenue growth of 14% in Q1 2024, primarily arising from our key Cloud ERP Business Lines, Dynamics and M3. EBITDA amounted to DKK 55m, corresponding to an EBITDA margin of 12.4%. Excluding a net gain of DKK 20m from settlement of M3CS legal case, the EBITDA margin was 7.9%. Overall, a satisfactory start to the year. “We came off to a good start of the year driven by strong performance in our Cloud ERP business. Our customers’ focus on safeguarding critical business systems is currently reshaping demand, thus un...
>Good, in-line Q2 results driven by metal gains - Aurubis this morning released good, in-line Q2 2023-24 (ended 31 March) results with operating EBITDA at € 179m, 3% below ODDO BHF and 2% below company-compiled consensus. The figure improved 13% q-o-q despite lower TC/RCs for concentrate (the benchmark stepped down to $ 80 and 8ct/lb on January 1 from $ 88.8 and 8.8ct in 2023). The pick-up was mostly driven by higher metal gains on the back of recent solid development...
>Q1 2024 beating expectations, driven by Europe and the US - Ahold Delhaize reported net sales and underlying EBIT of € 21,728m and € 861m in Q1 2024 (ABNe: € 21,348m and € 802m, consensus: € 21,530m and € 809m). Comparable growth amounted to 0.8% in the US and 2.8% in Europe. We had forecast 0.6% and -0.2% and consensus was 0.0% and 2.2%, respectively. The group underlying operating profit margin amounted to 4.0% (flat year on year), compared with our forecast and co...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.